Neurometrix Profit Margin

The latest profit margin for NURO is -257.38% as of December 2024. That compares with -108.34% in the prior-year period — down 137.6% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Neurometrix's historical trend and sector peers before judging valuation or financial health.

Over the past year, NURO's profit margin moved from -108.34% to -257.38% — a 137.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neurometrix's valuation or profitability profile.

Against Healthcare companies, NURO currently prints -257.38% for profit margin, while the sector average sits near 14.41%. That is roughly 1885.6% below the sector mean. Large gaps often invite a closer look at Neurometrix's growth, margins, and balance sheet.

Profit Margin shows how effectively Neurometrix converts resources into returns. At -257.38%, NURO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -108.34% in the prior-year period — down 137.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NURO's profit margin (-257.38%), review year-over-year change from -108.34%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.